Laser therapy and lomustine for recurrent glioblastoma
Treatments studied
Part of Cancer clinical trials.
This trial combines laser heat therapy (LITT) with the chemotherapy drug lomustine (CCNU) for people whose glioblastoma has returned. It aims to see if the combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have glioblastoma that has come back after previous treatment.
- You have had radiation therapy for your brain tumor before.
- You have not taken lomustine (CCNU) or bevacizumab (Avastin) before.
- You can swallow pills and are able to undergo laser brain surgery (LITT).
- Your overall health is good enough to participate (performance status 50 or higher).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a minimally invasive laser procedure combined with a new immunotherapy drug (cemiplimab) to treat glioblastoma that has returned after initial treatment. The laser heats and destroys the tumor while the immunotherapy helps your immune system fight remaining cancer cells.
This study tests whether combining imipramine (a medicine used for mood and sometimes nerve pain) with lomustine (a chemotherapy) can slow or treat recurrent glioblastoma that has come back after standard radiation and temozolomide. It is mainly for adults who are well enough to travel through treatment and monitoring scans and blood tests.
This trial studies a two-step treatment for newly diagnosed high-grade glioma: first laser treatment (LITT) to target the tumor, followed by a shorter, more focused course of radiation. It may help shrink or control the tumor while limiting treatment time.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
This trial tests a combination of two drugs, bortezomib and temozolomide, for people whose brain tumor (glioblastoma) has returned after initial treatment. It's designed for tumors that don't respond well to standard treatments, and the goal is to see if this combination can help control the cancer.
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.